| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/21/2002 | US20020034734 Vaccine composition for preventing or treating hepatitis C |
| 03/21/2002 | US20020034725 Sensitization of cells to radiation and and chemotherapy |
| 03/21/2002 | US20020034562 Cholesterol-free fat composition of linoleic acid, lauric acid, myristic acid, and palmitic acid, and elaidic acid for food products |
| 03/21/2002 | US20020034558 High water content with a glycoglyceride; skin, hair and lip cleansers and moisturizers |
| 03/21/2002 | US20020034557 Borage seed oil, Angelica pubescens root, Coleus forskohlii extract, vinpocetine, ferulic acid, magnesium, ascorbyl palmitate, capric/caprylic triglyceride, and silica; topical |
| 03/21/2002 | US20020034556 Citronella oil, geranium oil, rosemary oil, peppermint oil, D-limonene, aldehyde C-14 and aldehyde C-18 |
| 03/21/2002 | US20020034555 Acetaminophen or non-steroidal antiinflammatory drug, and a nutraceutical of a antivasospastic agent or a vascular dilator, and an antinausea agent or live protectant |
| 03/21/2002 | US20020034554 Enhancing permeation of skin or mucosal tissue with topical hydroxide- releasing agent and lipophilic co-enhancer |
| 03/21/2002 | US20020034546 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 03/21/2002 | US20020034545 Particulate composition of eletriptan |
| 03/21/2002 | US20020034544 Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine |
| 03/21/2002 | US20020034541 Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
| 03/21/2002 | US20020034540 Solid non-effervescent compressed dosage form comprising an ibuprofen medicament and an alkali metal carbonate or bicarbonate carrier material and compressible filler component combined with disintegrating component |
| 03/21/2002 | US20020034539 Biphasic multicomponent pharamaceutical dosage forms containing substances able to modify the partitioning of drugs |
| 03/21/2002 | US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations |
| 03/21/2002 | US20020034536 Novel particulate formulations |
| 03/21/2002 | US20020034535 Rate controlling membranes for controlled drug delivery devices |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020034527 Antioxidants |
| 03/21/2002 | US20020034502 Retroviral vectors |
| 03/21/2002 | US20020034499 Nutrient medium which can be used as a culture medium for epidermal cells and applications |
| 03/21/2002 | US20020034491 Administering cationic polymers |
| 03/21/2002 | US20020034485 Mixture of fatty acid, biotin and caffeine |
| 03/21/2002 | US20020034484 Vitamin/metal salt compositions for reducing hair loss and/or promoting hair regrowth |
| 03/21/2002 | US20020034482 Methods and compositions useful in enhancing oxygen delivery to cells |
| 03/21/2002 | US20020033181 Treatment of hepatitis C using hyperthermia |
| 03/21/2002 | US20020033174 Inhalable aerosol medicament for the treatment or prevention of pain |
| 03/21/2002 | US20020033144 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 03/21/2002 | DE10122893A1 Selektive PDE 2-Inhibitoren als Arzneimittel zur Verbesserung der Wahrnehmung Selective PDE 2 inhibitors as drugs to enhance cognition |
| 03/21/2002 | DE10045112A1 Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems The use of indole derivatives for the treatment of diseases of the central nervous system |
| 03/21/2002 | DE10045059A1 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen The therapeutic combination of lipoic acid and conjugated fatty acids for the treatment of diabetic disorders |
| 03/21/2002 | DE10044905A1 (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten (2-azabicyclo [2.2.1] hept-7-yl) methanol derivatives as nikontinische acetylcholine receptor agonists |
| 03/21/2002 | DE10044662A1 Cosmetic or pharmaceutical composition e.g. useful for skin cleansing or acne treatment, comprise salicylic acid, alkyl and/or alkenyl oligoglycosides and alkyl ether sulfates |
| 03/21/2002 | DE10026678C1 Transdermal patch for delivery of non-steroidal antiinflammatory agent, containing e.g. alkyl-pyrrolidone, metal salt, surfactant and polymers, provides good drug release and absorption properties |
| 03/21/2002 | CA2742411A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| 03/21/2002 | CA2687476A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422841A1 Methods for delaying recurrence of herpes virus symptoms |
| 03/21/2002 | CA2422829A1 Patch comprising diclofenac |
| 03/21/2002 | CA2422616A1 Gatifloxacin pentahydrate |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422278A1 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422229A1 Calcium binding proteins |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422093A1 Use of rhein for preparing a medicine for preventing articular cartilage damage |
| 03/21/2002 | CA2422064A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422044A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421966A1 Remedies for ischemic diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421652A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421585A1 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420529A1 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420504A1 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 03/21/2002 | CA2420493A1 Use of carnitine for enhancing training-induced bradycardia |
| 03/21/2002 | CA2420459A1 Novel dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420007A1 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419224A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/21/2002 | CA2416563A1 Pharmaceutical composition having specific water activity |
| 03/21/2002 | CA2406446A1 Diphosphonate solutions |
| 03/21/2002 | CA2391162A1 Novel topical oestroprogestational compositions with systemic effect |
| 03/21/2002 | CA2357467A1 Methods for treating osteoarthritis using an estrogen agonist/antagonist |
| 03/20/2002 | EP1188773A1 Nitroderivatives of polysaccharides |
| 03/20/2002 | EP1188769A2 High resolution crystal structure of the ribosome and design of protein synthesis inhibitors |
| 03/20/2002 | EP1188754A1 Substituted pyrazole compounds |
| 03/20/2002 | EP1188750A1 Process for the preparation of 2,5-diamino-4,6-dihalogenopyrimidinen |
| 03/20/2002 | EP1188447A1 Remedies for skin ulcer |
| 03/20/2002 | EP1188441A1 Oral preparations of etidronate disodium |
| 03/20/2002 | EP1188440A1 Medicinal composition for oral administration |
| 03/20/2002 | EP1188439A2 Cell differentiation induction with mevalonate and mevalonolactone derivatives |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1188437A2 Beta-hydroxybutyric acid or acetoacetic acid or salts or esters therof for use in improving cerebral function |
| 03/20/2002 | EP1188383A1 Method for production of arachidonic acid |
| 03/20/2002 | EP1188056A1 Use of gabapentin in assays to identify gabab receptor modulators |
| 03/20/2002 | EP1187929A2 Novel liposomal vector complexes and their use in gene therapy |
| 03/20/2002 | EP1187923A1 Apoptosis inhibition by adenovirus e3/6.7k |
| 03/20/2002 | EP1187918A1 Tek antagonists |
| 03/20/2002 | EP1187915A2 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 03/20/2002 | EP1187911A2 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 03/20/2002 | EP1187908A1 42 human secreted proteins |
| 03/20/2002 | EP1187854A1 Per(3,6-anhydro)cyclodextrin derivatives, preparation and use thereof for separating ions |
| 03/20/2002 | EP1187846A2 11beta long-chain substituted estratrienes, method for their production, pharmaceutical preparations containing said 11beta long-chain substituted estratrienes, and their use for producing medicaments |
| 03/20/2002 | EP1187838A1 Thiazolopyrimidines useful as tnf-alpha inhibitors |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187835A1 Optically active quinoline carboxylic acid derivatives having 7-pyrrolidine substitutes causing optical activity and a process for preparing thereof |
| 03/20/2002 | EP1187834A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |
| 03/20/2002 | EP1187832A1 Amino heterocycles useful as pharmaceutical agents |
| 03/20/2002 | EP1187831A1 Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives |